In Vitro Activity of Tigecycline and Colistin against clinical isolates of Acinetobacter baumannii in Hospitals in Tehran and Bandar-Abbas, Iran
Keywords:
Acinetobacter baumannii; Polymyxin-B, Colistin; TigecyclineAbstract
Background: The Acinetobacter species, particularly A. baumannii, has emerged as one of the main causes of nosocomial infections in recent years. The high prevalence of drug resistance in A. baumannii limits the therapeutic options for treating infections caused by these bacteria. The objective of this study was to determine the in vitro activity of Tigecycline and Colistin against clinical isolates of A. baumannii in Tehran and Bandar Abbas, Iran.
Methods: This study was conducted from March 2009 to November 2010 at three hospitals in Tehran and Bandar Abbas, Iran, using 165 Acinetobacter species isolated from clinical specimens. All isolates were subjected to PCR to detect blaOXA-51-like genes that are unique to Acinetobacter baumannii. Isolates that gave a band for the blaOXA-51-like genes were identified as A. baumannii. Anti-microbial susceptibility tests were performed for Tigecycline, Colistin, and other antibiotics.
Results: Sensitivity rates to Colistin and Polymyxin-B were 100%. Resistance rates for Tigecycline were 4.2% in Tehran and 8.8% in Bandar-Abbas according to Jones criteria, whereas, according to U.S. FDA criteria, the resistance rates were 20.8% and 17.6%, respectively.
Conclusions: New alternative drugs are needed for the treatment of drug resistant A. baumannii. Although Colistin appears to be a good choice, adverse reactions have limited its usage. Tigecycline is effective against A. baumannii isolates, and it shows promise for solving the problem.
References
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinicalmicrobiology reviews. 2008;21(3):538-82. Epub 2008/07/16. PMCID: 2493088. PMID:18625687.DOI:10.1128/CMR.00058-07, URL:http://dx.doi.org/10.1128/CMR.00058-07.2.Tan TY, Ng LS, Poh K. Susceptibilitytesting of unconventional antibiotics against multiresistantAcinetobacter spp. by agar dilution and Vitek 2. Diagnostic microbiology and infectious disease.2007;58(3):357-61. Epub 2007/05/01. PMID:17467946.DOI:10.1016/j.diagmicrobio.2007.02.008, URL:http://dx.doi.org/10.1016/j.diagmicrobio.2007.02.008.3.Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility amongmultidrug-resistant Acinetobacterbaumannii isolated from ventilator-associated pneumonia. InternationalJournal of Antimicrobial Agents. 2008;32(1):29-32. PMID:18539006. DOI: v, URL:http://dx.doi.org/http://dx.doi.org/10.1016/j.ijantimicag.2008.02.016.4.Park YK, Choi JY, Shin D, Ko KS. Correlation between overexpression and amino acid substitution of thePmrAB locus and colistin resistance in Acinetobacter baumannii. International Journal of AntimicrobialAgents. 2011;37(6):525-30. PMID:21497062. DOI:10.1016/j.ijantimicag.2011.02.008, URL:http://dx.doi.org/http://dx.doi.org/10.1016/j.ijantimicag.2011.02.008.5.Wang YF, Dowzicky MJ. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolatescollected from patients with bacteremia and MIC change during the Tigecycline Evaluation andSurveillance Trial, 2004 to 2008. Diagnostic microbiology and infectious disease. 2010;68(1):73-9. Epub2010/08/24. PMID: 20727474. DOI: v, URL:http://dx.doi.org/10.1016/j.diagmicrobio.2010.04.002.6.Jamal W, Salama M, Dehrab N, Al Hashem G, Shahin M, Rotimi VO. Role of tigecycline in the control ofa carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. Journal of HospitalInfection. 2009;72(3):234-42.http://dx.doi.org/http://dx.doi.org/10.1016/j.jhin.2009.03.023.7.Bouchillon SK, Hoban DJ, Johnson BM, Stevens TM, Dowzicky MJ, Wu DH, et al. In vitro evaluation oftigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagnostic microbiology andinfectious disease. 2005;51(4):291-5. PMID:15808321. DOI:10.1016/j.diagmicrobio.2004.11.006, URL:http://dx.doi.org/http://dx.doi.org/10.1016/j.diagmicrobio.2004.11.006.8.Schreckenberger PC vGA. Manual of Clinical Microbiology,7th ed. 1997: 539-60.9.Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of Acinetobacterbaumannii by Detection of the blaOXA-51-like Carbapenemase GeneIntrinsic to This Species. Journal ofClinical Microbiology. 2006;44(8):2974-6. PMID:16891520. PMCID: 1594603. DOI:10.1128/jcm.01021-06, URL:http://dx.doi.org/10.1128/jcm.01021-06.10.Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al.Antimicrobial susceptibility patterns and distribution of blaOXA genes among Acinetobacter spp. Isolatedfrom patients at Tehran hospitals. Japanese journal of infectious diseases. 2008;61(4):274-8. Epub2008/07/26. PMID:1865396811.PA W. Clinical and Laboratory Standard Institute: Performance standards for antimicrobial susceptibilitytesting, Seventeenth informational supplement. CLSI document M100 S17. USA 200712.Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies oftigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol. 2007;45(1):227-30.Epub 2006/11/10. PMCID: 1828968. PMID:17093026. DOI:10.1128/jcm.01588-06, URL:http://dx.doi.org/10.1128/jcm.01588-06.13.Liao CH, Kung HC, Hsu GJ, Lu PL, Liu YC, Chen CM, et al. In-vitro activity of tigecycline againstclinical isolates of Acinetobacter baumanniiin Taiwan determined by the broth microdilution and diskdiffusion methods. Int J Antimicrob Agents. 2008;32 Suppl 3:S192-6. Epub 2008/12/17.DOI:10.1016/s0924-8579(08)70027-x, URL:http://dx.doi.org/10.1016/s0924-8579(08)70027-x.14.Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation andSurveillance Trial. TheJournal of infection. 2007;55(1):49-57. PMID:17250897.Epub 2007/01/26.DOI:10.1016/j.jinf.2006.11.018, URL:http://dx.doi.org/10.1016/j.jinf.2006.11.018.15.Tiengrim S, Tribuddharat C, Thamlikitkul V. In vitro activity of tigecycline against clinical isolates ofmultidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand. Journal of the MedicalAssociation of Thailand = Chotmaihet thangphaet. 2006;89 Suppl 5:S102-5. Epub 2007/08/28.16.Curcio D, Fernandez F, Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, et al. Tigecycline diskdiffusion breakpoints of Acinetobacter spp.: a clinical point of view. J Clin Microbiol. 2007;45(6):2095;author reply-6. Epub 2007/06/06.PMCID: 1933103.DOI:10.1128/jcm.00107-07, URL:http://dx.doi.org/10.1128/jcm.00107-07.17.Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Famiglietti A. Selection of colistin-resistantAcinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with highpresence of heteroresistance to colistin. Diagnostic microbiology and infectious disease. 2009;65(2):188-91. Epub 2009/09/15. PMID:19748431.DOI:10.1016/j.diagmicrobio.2009.05.019, URL:http://dx.doi.org/10.1016/j.diagmicrobio.2009.05.019.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Knowledge Kingdom Publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
